Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA

An upcoming NDA filing for Hemispherx' chronic fatigue syndrome agent Ampligen may offer a sensitive case for FDA as it implements Commissioner McClellan's "strategic plan" for the agency